[
    "</sup>), \u2014NR<sup>3</sup>(CO)R<sup>3</sup>, \u2014(CO)N(R<sup>3</sup>)<sub>2</sub>.</p>In one embodiment, the invention provides a compound selected from the compounds of Table 1, or pharmaceutically acceptable salts thereof.</p>Compounds described herein (e.g., a compound of Formula (I), (Ia), (II), (IIa), (IIa1), (IIa1i), (IIa2), (IIa2i), (IIa3), (IIa3i), (IIa3ii), (IIa3), (IIa4), (IIa4i), (III), (IIIa), (IIIa1), (IIIa1i), (IIIa2), (IIIa2i), (IIIa2ii), (IV), (IVa), (V), (Va), (Va1), (Va2), (Va3), (VI), (VIa), (VIb), (VII), (VIIa), (VIIa1), (VIIa1i), (VIIb), (VIIb1), (VIIb1i) or a compound of Table 1, or pharmaceutically acceptable salts thereof) are useful as inhibitors of PRMT5 (e.g., MTA uncompetitive PRMT5 inhibitors).</p>Table 1 indicates IC<sub>50 </sub>values (\u03bcM) against PRMT5 for exemplary compounds in the presence of SAM as cofactor, with no cofactor and with MTA as cofactor, respectively (columns 3-5). For Table 1, \u201ca\u201d \u201caa\u201d and \u201caaa\u201d indicates an IC<sub>50 </sub>less than 50 nM in the assays with SAM, no cofactor and MTA respectively; \u201cb\u201d, \u201cbb\u201d and \u201cbbb\u201d indicates an IC<sub>50 </sub>of 50 nM to less than 500 nM in the assays with SAM, no cofactor and MTA, respectively; \u201cc\u201d, \u201ccc\u201d and \u201cccc\u201d indicates an IC<sub>50 </sub>of greater than or equal to 500 nM to less than 5 \u03bcM in the assays with SAM, no cofactor and MTA, respectively; \u201cd\u201d, \u201cdd\u201d and \u201cddd\u201d indicates an IC<sub>50 </sub>of greater than or equal to 5 \u03bcM in the assays with SAM, no cofactor and MTA, respectively. The Ki values can be calculated from the IC<sub>50 </sub>values as described in the Examples section. As detailed in the Examples section, for the assay performed in the presence of SAM, IC<sub>50</sub>=Ki\u00d71.5 (Ki=IC<sub>50</sub>/1.5). For the assay performed in the presence of MTA, IC<sub>50</sub>=Ki\u00d713.5 (Ki=IC<sub>50</sub>/13.5). Column 6 indicates the ratio between the Ki of compounds in the presence of SAM and the Ki of compounds in the presence of MTA</p>In column 6, \u201cA\u201d indicates a Ki ratio greater than or equal to 10 fold between the Ki in the presence of SAM and the Ki in the presence of MTA; \u201cB\u201d indicates a Ki ratio greater than or equal to 3 fold but lower than 10 fold between the Ki in the presence of SAM and the Ki in the presence of MTA; \u201cC\u201d indicates a Ki ratio of less than 3 fold between the IC<sub>50 </sub>in the presence of SAM and the IC<sub>50 </sub>in the presence of MTA; Compounds with a SAM/MTA ratio of more than 1 show greater cooperativity with MTA than with SAM.</p>Table 1 also indicates IC<sub>50 </sub>values in an MTAP-isogenic cell line pair for exemplary compounds in an SDMA in-cell western assay (columns 7-8). HAP1 MTAP-intact is a cell line in which endogenous levels of MTAP are expressed, and HAP1 MTAP-deleted is an MTAP-null cell line. For Table 1, \u201ca*\u201d and \u201caa*\u201d indicates an IC<sub>50 </sub>of &lt;1 \u03bcM, \u201cb*\u201d and \u201cbb*\u201d indicates an IC<sub>50 </sub>equal to or greater than 1 \u03bcM but less than 10 \u03bcM, and \u201cc*\u201d and \u201ccc*\u201d indicates an IC<sub>50 </sub>of greater than or equal to 10 \u03bcM in the HAP1 MTAP-intact and the HAP1 MTAP-deleted assays, respectively. In column 9, \u201cA*\u201d indicates an IC<sub>50 </sub>ratio greater than or equal to 10 fold between the IC<sub>50 </sub>in the HAP1 MTAP-intact cell line and the HAP1 MTAP-deleted cell line; \u201cB*\u201d indicates an IC<sub>50 </sub>ratio greater than or equal to 3 fold but lower than 10 fold between the IC<sub>50 </sub>in the HAP1 MTAP-intact cell line and the HAP1 MTAP-deleted cell line; \u201cC*\u201d indicates an IC<sub>50 </sub>ratio of less than 3 fold between the IC<sub>50 </sub>in the HAP1 MTAP-intact cell line and the HAP1 MTAP-deleted cell line. Compounds with a ratio in the SDMA in-cell western assay of equal to or greater than 3 fold are considered MTAP-selective.</p>Unles",
    "80\u00b0 C. The reaction may be carried out in solvents such as but not limited to DMF, and MTBE.</p>Compounds of formula 1-3 and 1-3a can undergo MoM and Boc deprotection using conditions known to one of skill in the art to give compounds of formula 1-4 and 1-4a. For example, Boc deprotection may comprise treatment with an acid. Exemplary acids include TFA, and HCl, and exemplary solvents include protic solvents such as methanol, halogenated solvents such as DCM and hexafluoroisopropanol or ether solvents such as dioxane and dimethylether. Compounds of formula 1-4 and 1-4a may be isolated as a salt or converted to the free base.</p>Compounds of formula 1-4 and 1-4a can be Boc protected using Boc anhydride (Boc<sub>2</sub>O) in a solvent such as DMF, THF, H<sub>2</sub>O, MeOH, DCM or a mixture thereof, optionally in the presence of a base. Exemplary bases include carbonate bases such as K<sub>2</sub>CO<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, and amine bases such as DBU, NEt<sub>3</sub>, and NEt(<sup>i</sup>Pr)<sub>2</sub>.</p>Compounds of formula 1-5 and 1-5a can be coupled with alkyl chlorides of formula 1-6 under N-alkylation conditions to yield compounds of formula 1-7 and 1-7a, respectively. Examples of conditions known to generate compounds of formula 1-7 and 1-7a from a mixture of compounds of formula 1-5 and an alkyl chloride of formula 1-6 include but are not limited to adding one or more bases with or without an iodide salt. Exemplary iodide salts include such as NaI, KI and tetra-n-butylammonium iodide. Exemplary bases include carbonate bases such as K<sub>2</sub>CO<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, and amine bases such as DBU, NEt<sub>3</sub>, and NEt(<sup>i</sup>Pr)<sub>2</sub>. The reaction may be carried out in solvents such as but not limited to DMF, acetonitrile and ethanol. The reaction may be heated at a temperature such as the reflux temperature of the solvent, or at a temperature in a range of 70\u00b0 C. to 100\u00b0 C., or in a range of 85\u00b0 C. to 95\u00b0 C., or at 90\u00b0 C., or at 75\u00b0 C.</p>Compounds of formula 1-7 and 1-7a can undergo Boc deprotection using conditions known to one of skill in the art to give compounds of formula I and Ia, respectively. For example, Boc deprotection may comprise treatment with an acid. Exemplary acids include TFA, and HCl, and exemplary solvents include protic solvents such as methanol, halogenated solvents such as DCM and hexafluoroisopropanol or ether solvents such as dioxane and dimethylether. Compounds of formula I and Ia may be isolated as a salt or converted to the free base.</p>SYNTHESIS OF INTERMEDIATE ACIDSSynthesis of Acids of Formula Acid-IIa2i<img id=\"EMI-C00177\" path=\"US20230054084A1-20230223-C00177.TIF\" file=\"https://surechembl.org/api/assets/attachment/1030911474/US/20230223/A1/020230/05/40/84/US20230054084A1-20230223-C00177.TIF\"/></p>wherein A and R<sup>x </sup>are as described herein and LG<sup>a </sup>and LG<sup>b </sup>are leaving groups as described herein.</p>In certain embodiment",
    "7.5 nM Me0 in assay buffer was prepared.1.5\u00d7Me0 (Min control): 37.5 nM Me0 in assay buffer was prepared.\n        </p>Assay Procedure:Above reagents were prepared5 \u03bcL 3\u00d7 cofactor solution was dispensed to wells in all columns by 16-channel electronic pipettesAssay plate containing compound was spinned 60 sec at 1000 rpm10 \u03bcL Min control (peptide) solution was dispensed to the wells (columns 1&amp;13) by 16-channel electronic pipettes10 \u03bcL enzyme (1.5\u00d7enzyme/peptide) solution was dispensed to the wells (columns 2-12&amp;14-24) by 16-channel electronic pipettesAssay plate containing compound was spinned 60 sec at 1000 rpm, and incubated at 23\u00b0 C. for 30 minProcedure was repeated for other three assay conditions and all plates were incubated for 30 minAssay plate was read on Envision instrument</p>Data AnalysisFluorescence polarization is normalized to calculate % inhibition.</p>%\u2062   inhibition-i=(1-i-PPrmt\u20625\u2062_\u2062P-P)*100Equation\u2062   1</p>Where:% inhibition is the percentage inhibition at a given concentration of inhibitor\n\ni is the Fluorescent anisotropy at a given inhibitor concentration\n\nP is the anisotropy signal given by the peptide alone and represents the minimum signal\n\nPrmt5_P is the anisotropy signal given by the Prmt5 and peptide complex in the presence of DMSO, representing the maximum fluorescent anisotropy signal\n% inhibition data were fit with a 4-parameter logistic model. Bottom and Top were fixed to 0% and 100%, respectively. IC<sub>50 </sub>values are reported.The Ki can be calculated from the IC<sub>50 </sub>using the Cheng-Prussof equation:\n</p>IC50-Ki\u00d7(1+[Peptide]Kd,Peptide)For the assay performed in the presence of SAM, the Me2 peptide binding affinity to PRMT5 in the presence of SAM was determined to be 50 nM, and the peptide concentration is 25 nM, therefore IC<sub>50</sub>=Ki\u00d71.5For the assay performed in the presence of MTA, the Me0 peptide binding affinity to PRMT5 in the presence of MTA was determined to be 2 nM, and the peptide concentration is 25 nM, therefore IC<sub>50</sub>=Ki\u00d713.5</p>Envision\u00ae Set Up:Mirror (Barcode 682)Filter (Barcode 245)Filter (Barcode 246)Filter (Barcode 132)\n\nThe data for this example is shown in Table 1, Columns 3-6.\n</p>Example 11\u2014Cellular Assay\u2014SDMA In-Cell Western ProtocolA HAP1 MTAP-isogenic cell line pair was acquired from Horizon Discovery (HZGHC004894c005) and maintained in DMEM (ThermoFisher 11965)+10% FBS (Gemini 100-500) in a humidified, 10% CO<sub>2 </sub>tissue culture incubator. The SAM-cooperative PRMT5 inhibitor, GSK3326595, was sourced from SelleckChem and maintained as a 10 mM DMSO stock. All test compounds are maintained as 10 mM DMSO stocks.</p>On Day 0, MTAP-intact or MTAP-deleted cells are seeded in a 384-well plate, and incubated in a humidified, 10% CO<sub>2 </sub>tissue culture incubator for 16-24 hours. On Day 1, the test compounds are dispensed to wells at defined concentrations using a Tecan D300e digital dispenser (n=4), and the volume of DMSO is normalized to highest class volume. Each plate includes wells dosed with defined concentrations of GSK33226595 as a plate control. The compounds are incubated with cells for 24 hours in a humidified, 10% CO<sub>2 </sub>tissue culture incubator.</p>On Day 2, the compound-treated cells are fixed with a final concentration of 4% formaldehyde. The cells are then washed/permeabilized with 1\u00d7PBS+0.1% Triton X-100, and then blocked with 5% goat serum/1\u00d7TBS. The fixed cells are then incubated overnight at 4\u00b0 C. with a primary SDMA antibody cocktail (Cell Signa"
]